Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

摘要: OBJECTIVE To describe changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of HIV-2-infected patients receiving antiretroviral (ARV) therapy Abidjan, Cote d'Ivoire. METHODS Consecutive blood samples were collected from 18 ARV-naive who had received ARV the UNAIDS access initiative (UNAIDS-DAI) Abidjan between August 1998 July 2000. Changes HIV-2 genotypic phenotypic testing determined. RESULTS At baseline, 11 (61%) initiated highly active (HAART) seven (39%) dual therapy. No significant change median load was observed at 2 months (P = 0.09), 6 0.06), 12 0.26). increase counts 0.10). All four on indinavir-containing HAART undetectable loads 2-4 However, none nelfinavir-containing a substantial decrease load. Viruses 14 analyzed, which (86%) least one primary mutation that is known to confer HIV-1 virus. Three multi-drug-resistant mutation, Q151M, two whom showed reduced susceptibility zidovudine, didanosine, stavudine zalcitabine. CONCLUSION Our limited findings show regimens may have virologic benefit patients.